PORTFOLIO

Most of my work is confidential and cannot be shared. However, I have a lot of experience in scientific publishing and have worked on many abstracts, posters and manuscripts across a broad range of therapy areas.

I have listed below some publications where I am acknowledged as providing medical writing support or that I have authored, grouped by therapy area.

The full list can also be downloaded here.

I've also written a series of blog posts that showcase my writing skills.

AUTOIMMUNE DISEASE

Tanaka Y, et al. Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study. Lupus Science and Medicine 2025; online ahead of print.

Fossati C, et al. Single-centre experience with tralokinumab in dupilumab-experienced and naive patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2024; 39(2):e184–186.

Day K, et al. Addressing educational gaps through multidisciplinary team education in eosinophilic oesophagitis management. J CME 2023; 12:223033.
Tanaka Y, et al. The management of women of child-bearing age with rheumatoid arthritis: an expert report. Expert Rev Clin Immunol 2023; 19:655-669.
Changing the way babies eat: Supporting early allergen feeding around the world. EMJ 2022; 7:33-41.
Sabet A, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther 2022; 9:693-704.
Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021; 14:17562848211059954.

Taylor PC, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med 2021; 10(3):509.
Hercogová J, et al. AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2020; 182:316-26.
Edwards C, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol 2019; 38:3381-3390.
Hercogová J, et al. Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the proposed biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-week, phase III study in moderate-to-severe plaque-type psoriasis patients. Presented at the American Academy of Dermatology Annual Meeting 2019.
Baumgart DC, et al. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front Pharmacol 2019; 10:279.
Edwards CJ, et al. Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019; 19:1001-14.

CARDIOVASCULAR AND METABOLIC DISEASES

Dimmeler S, et al. Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J 2025. Online ahead of print.
Mahaffey K, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J 2024; Online ahead of print.

Verma S, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): Outcomes by sex. J Am Coll Cardiol 2024; Online ahead of print.

Gabe MBN, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes Obes Metab 2024; 26(10):4480–89.

Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2024; 12:184-195.

Umemura I, et al. Relationship between left ventricular ejection fraction and treatment characteristics in hospitalized patients with heart failure – A Japanese database analysis. Circ Rep 2023; 5(10):392-402.

Okemah J, et al. Impact on knowledge, competence and performance of a faculty-led web-based educational activity for type 2 diabetes and obesity: Questionnaire study among health care professionals and analysis of anonymized patient records. JMIR Form Res 2023; 7:e49115.

Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asian population with overweight or obesity in the STEP 7 randomised clinical trial. Presented at the 30th European Congress on Obesity, 17-20 May 2023.

Suzuki S, et al. Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry. PLoS ONE 2023; 18(2): e0280753.

Harris SB, et al. The educational impact of online, faculty-led continuing medical education programs in type 2 diabetes: An analysis of changes in the knowledge, competence, and performance of healthcare professionals. JMIR Med Educ 2022; 8(4): e40520.

Nguyen-Thi H-Y, et al. Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE trial in Vietnam. Front Public Health 2020; 8:56203.

Klein H and Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ 2017; 20:640-45.

Hinchliffe E, Carter S, et al. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 15:913-914.

Carter S, et al. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012; 49:570-9.

HAEMOPHILIA

Realising the Promise of Gene Therapy for Haemophilia: Current Status and Future Innovations. EMJ 2023; 11[1]:2-11.

Gene therapy in haemophilia: Updates from clinical trials and insights to future technologies. EMJ 2022; 10[5]:2-12.

Klamroth R, et al. Illustrative cases from the pathfinder clinical trials of patients with hemophilia A treated with turoctocog alfa pegol (N8-GP). Pat Pref Adher 2021; 15: 2443-54.

INFECTIOUS DISEASES

Kirste I, et al. Quantifying the vaccine-induced humoral immune response to spike-receptor binding domain as a surrogate for neutralization testing following mRNA-1273 (Spikevax) vaccination against COVID-19. Infect Dis Ther 2023; 12:177-191.

Taffertshofer K, et al. Design and performance characteristics of the Elecsys Anti-SARS-CoV-2 S assay. Front Immunol 2022; 13:1002576.

Bosheva M, et al. A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatr Infect Dis 2021; 40: e222-9.

Overcash JS, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis 2021; 73: e1507-17.

Welte T, et al. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol 2021; 16:543-555.

Hamed K, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol 2020; 15:35-48.

Hamed K, et al. No evidence for ceftobiprole-induced immune hemolytic anemia in three Phase 3 clinical trials. Infect Drug Resist 2020; 13:3461.

Stemler J, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses 2020; 63:1060-68.

ONCOLOGY

Köhler B, et al. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis. Int J Biol Markers 2024; 39:107-17.

Zhao C, et al. Opportunities and challenges for human papillomavirus vaccination in China. Hum Vaccin Immunother 2024; 20:2329450.

Gnant M, et al. Assessing knowledge, competence, and performance following web-based education on early breast cancer management: Healthcare professional questionnaire study and anonymized patient records analysis. JMIR Form Res 2024; 8:e50931.

Muley T, et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Tumor Biology 2024;46:S219-232.

Xia L, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecologic Cancer 2023; 33(12)1861-8.

Xu Y, et al. Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer. An open-label, single-arm, multicentre study. Lung Cancer 2023; 183:107288.

Management of thrombosis in high-risk patients: Focus on cancer-associated thrombosis. EMJ 2022; 7[3]:30-39.

Gibbs H, Klok FA. New developments, data, and guideline updates: Direct oral anticoagulants for the treatment of venous thromboembolism associated with cancer - interviews with key opinion leaders. EMJ 2022; 10(Suppl 3):2-8.

Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011; 30:4921-30.

Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011; 10:3176-88.

Carter S and Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.

Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28.

Carter S and Vousden KH. A role for Numb in p53 stabilization. Genome Biol 2008; 9:221.

Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol 2007; 9:428-35.

Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279:52835-9.

Hammond DE, Carter S, et al. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004; 286:21-44.

Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14: 1346-54.

OTHER

Castro D, et al. Transition of patients with Duchenne muscular dystrophy from paediatric to adult care: an international Delphi consensus study. Eur J Paediatr Neurol 2025; 54:130–9.

Hamada I, et al. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex. J Dermatol 2024; 51:752-8.

Zhou J, et al. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. J Headache Pain 2023; 24:103.

Abukhaled M, et al. Case report: Aromatic L-amino acid decarboxylase deficiency in three patient cases from the Kingdom of Saudi Arabia. Eur J Pediatr 2023; 182:2535-2545.

Abukhaled M, et al. Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review. Front Pediatr 2023; 10:1016239.

Alho H, et al. Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy 2020; 76:102616.

Kakko J, et al. Craving in opioid use disorder: From neurobiology to clinical practice. Front Psychiatry 2019; 10:592.

Chin KM, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Circulation 2019; 139:2440-50.

Torbicki A, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases. Circ Cardiovasc Qual Outcomes 2019; 12:e005095.

Berger RMF, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83:1734-44.

Anchor 1

Anchor 2

Haemophilia

Infectious diseases

Oncology

Other